The pharmaceutical industry in Australia is facing a crisis as the country's Pharmaceutical Benefits Scheme (PBS) struggles to keep up with the latest innovations in global medicine. This has led to a situation where patients are missing out on life-changing treatments, and pharmaceutical companies are turning away from the Australian market due to a complex and lengthy approvals process. The Trump administration's global pricing pressures are exacerbating this issue, making the Australian market less commercially attractive. This article explores the impact of this crisis on patients and the pharmaceutical industry, and delves into the underlying causes of the delays in approvals, including Australia's process for assessing cost-effectiveness and the influence of global pricing pressures. It also examines the potential solutions being considered by the Australian government, including a Health Technology Assessment (HTA) review, and the challenges faced by the industry in the face of these pressures.
